Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Multiple Myeloma Would Make Good Guinea Pig For Oncology Cost Control

Sep 28 2016

• By Emily Hayes

Related Content

Amgen's Kyprolis Miss In First-Line Myeloma Surprising, But Clinically Irrelevant

Sep 27 2016

Another Sea Change In Myeloma Promised By New Therapies, Combos

Jun 15 2016

WellPoint Cancer Drug Pathways Program Aims To Save 4% In Annual Costs

May 28 2014

Cancer Pathways Will Help Inform Drug Performance Measures, Payers Say

Apr 02 2012

Myeloma Drug Access Limits Unlikely Near-term – Aetna, Express Scripts Say

May 27 2016

Multiple Myeloma Market Snapshot: New Drugs And Big Changes

Jan 04 2016

ICER Questions Cost Effectiveness Of Empliciti, Kyprolis, Ninlaro

Apr 08 2016

Emergence Of New Myeloma Drugs, And Combinations, Raises Red Flag On Costs

Jun 29 2015

Related Companies

Takeda Pharmaceutical Co. Ltd.

Bristol Myers Squibb Company

Amgen, Inc.

Johnson & Johnson

Bristol Myers Squibb Company

Novartis AG

Merck & Co., Inc.

Express Scripts Holding Company

Anthem Inc.

Additional Topics

Market Access Reimbursement Pricing Strategies Cancer BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window